Postconception menses induction using prostaglandin vaginal suppositories.
Vaginal suppositories containing 15 methyl prostaglandin F2 alpha methyl ester in a high-melt base were administered to 60 women desiring early pregnancy interruption who were no more than 56 days' (eight weeks) pregnant as calculated from the first day of the last regular menstrual period (LMP). The purpose of this study was to evaluate the safety, efficacy, and patient acceptability of this mode of noninvasive early abortion. Some factors evaluated during the study included the time interval from insertion of the suppository to the onset of cramping and bleeding. Also measured were immediate and delayed blood loss, nausea, vomiting, and diarrhea. Of the 60 patients entered into the study, 55 procedures have been judged as successful by the prospective criteria set forth in the protocol. There were no deaths or serious complications. Four patients required hospitalization and follow-up dilatation and curettage (D&C). One patient withdrew from the study after receiving a suppository and subsequently delivered a preterm infant.
D000028:Abortion, Induced / Q000379:methods*; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D009325:Nausea / Q000139:chemically induced; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011453:Prostaglandins / Q000009:adverse effects / Q000494:pharmacology*; D012449:Safety; D013488:Suppositories; D014590:Uterine Contraction / Q000187:drug effects; D014621:Vagina; D014839:Vomiting / Q000139:chemically induced
D011453:Prostaglandins; D013488:Suppositories